Onapristone + Fulvestrant
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ER-positive Breast Cancer
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Trial Timeline
Oct 5, 2021 → May 15, 2023
NCT ID
NCT04738292About Onapristone + Fulvestrant
Onapristone + Fulvestrant is a phase 2 stage product being developed by Context Therapeutics for ER-positive Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04738292. Target conditions include ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer.
What happened to similar drugs?
0 of 2 similar drugs in ER-positive Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04738292 | Phase 2 | Terminated |
Competing Products
6 competing products in ER-positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fulvestrant Run-In | Eli Lilly | Phase 2 | 42 |
| AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib | AstraZeneca | Phase 3 | 44 |
| AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist | AstraZeneca | Phase 3 | 44 |
| [14C]AZD9833 Oral Solution, 75 mg | AstraZeneca | Phase 1 | 29 |
| AZD9833 + Fulvestrant | AstraZeneca | Phase 2 | 39 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 39 |